- Home
- BTBT vs SNDX Comparison
BTBT vs SNDX Comparison
Compare BTBT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- SNDX
- Stock Information
- Founded
- BTBT 2015
- SNDX 2005
- Country
- BTBT United States
- SNDX United States
- Employees
- BTBT N/A
- SNDX N/A
- Industry
- BTBT Finance: Consumer Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BTBT Finance
- SNDX Health Care
- Exchange
- BTBT Nasdaq
- SNDX Nasdaq
- Market Cap
- BTBT 1.1B
- SNDX 1.1B
- IPO Year
- BTBT 2018
- SNDX 2016
- Fundamental
- Price
- BTBT $2.97
- SNDX $15.13
- Analyst Decision
- BTBT Strong Buy
- SNDX Strong Buy
- Analyst Count
- BTBT 3
- SNDX 10
- Target Price
- BTBT $6.33
- SNDX $38.40
- AVG Volume (30 Days)
- BTBT 21.4M
- SNDX 2.0M
- Earning Date
- BTBT 08-14-2025
- SNDX 11-04-2025
- Dividend Yield
- BTBT N/A
- SNDX N/A
- EPS Growth
- BTBT N/A
- SNDX N/A
- EPS
- BTBT N/A
- SNDX N/A
- Revenue
- BTBT $98,402,256.00
- SNDX $77,933,000.00
- Revenue This Year
- BTBT $16.34
- SNDX $585.73
- Revenue Next Year
- BTBT $44.80
- SNDX $94.17
- P/E Ratio
- BTBT N/A
- SNDX N/A
- Revenue Growth
- BTBT 13.30
- SNDX 2126.66
- 52 Week Low
- BTBT $1.69
- SNDX $8.58
- 52 Week High
- BTBT $5.74
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- BTBT 55.95
- SNDX 50.41
- Support Level
- BTBT $2.86
- SNDX $15.71
- Resistance Level
- BTBT $3.16
- SNDX $16.50
- Average True Range (ATR)
- BTBT 0.17
- SNDX 0.82
- MACD
- BTBT 0.05
- SNDX -0.31
- Stochastic Oscillator
- BTBT 75.51
- SNDX 5.10
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.